The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
First-in-human results of terbium-161[161Tb]Tb-PSMA-I&T radioligand treatment in patients with metastatic castration-resistant prostate cancer (VIOLET): A single-centre, single-arm, phase I/II study.
 
James Buteau
No Relationships to Disclose
 
Louise Kostos
Honoraria - Bayer
 
Price Jackson
No Relationships to Disclose
 
Lachlan McIntosh
No Relationships to Disclose
 
Ramin Alipour
No Relationships to Disclose
 
Timothy Akhurst
Employment - Intelerad (I)
Stock and Other Ownership Interests - Perkin Elmer (I)
 
Michal Eifer
No Relationships to Disclose
 
Brittany Emmerson
No Relationships to Disclose
 
Mohammad Haskali
No Relationships to Disclose
 
Kerry Jewell
No Relationships to Disclose
 
Raghava Kashyap
No Relationships to Disclose
 
Grace Kong
Consulting or Advisory Role - ITM Isotope Technologies Munich
Speakers' Bureau - Ipsen; Novartis
Research Funding - Cyclotek; ITM Isotope Technologies Munich; Pfizer
 
Declan Murphy
Honoraria - Astellas Pharma; AstraZeneca; Bayer; Ferring; Ipsen; Janssen Oncology; Novartis
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Bayer; Bayer Schering Pharma; Janssen Oncology
Travel, Accommodations, Expenses - Device Technologies
 
Aravind Ravi Kumar
Research Funding - Varian Medical Systems (Inst)
Travel, Accommodations, Expenses - Janssen Oncology
 
Javad Saghebi
No Relationships to Disclose
 
Shahneen Sandhu
Honoraria - Abbvie (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Janssen (Inst); Merck (Inst); Merck Serono (Inst); Novartis (Inst); Skyline Diagnostics (Inst)
Consulting or Advisory Role - Abbvie (Inst); AstraZeneca (Inst); Bristol Myers Squibb (Inst); Merck Sharp and Dohme (Inst); Novartis (Inst); Roche/Genentech (Inst); Skyline Diagnostics (Inst)
Research Funding - Amgen (Inst); AstraZeneca (Inst); Bristol-Myers Squibb (Inst); Endocyte/Advanced Accelerator Applications (Inst); Genentech/Roche (Inst); Merck (Inst); Novartis (Inst); Pfizer (Inst); Senhwa Biosciences (Inst)
(OPTIONAL) Uncompensated Relationships - AAA/Endocyte/Novartis (Inst)
 
Ben Tran
Honoraria - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Janssen; Janssen-Cilag; Pfizer; Sanofi; Tolmar
Consulting or Advisory Role - Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Ipsen; IQvia; Janssen-Cilag; MSD Oncology; Novartis; Pfizer/EMD Serono; Pfizer/EMD Serono; Roche Molecular Diagnostics; Sanofi; Tolmar
Research Funding - Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); Bristol-Myers Squibb; Genentech (Inst); Ipsen; Janssen-Cilag (Inst); Merck Sharp & Dohme; Pfizer (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma
 
Jing Xie
No Relationships to Disclose
 
Arun Azad
Honoraria - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Consulting or Advisory Role - Aculeus Therapeutics; Amgen; Astellas Pharma; AstraZeneca; Bayer; Bristol-Myers Squibb; Daiichi Sankyo; Ipsen; Janssen; Merck Serono; Merck Sharp & Dohme; Merck Sharp & Dohme; Novartis; Noxopharm; Pfizer; Sanofi; Telix Pharmaceuticals; Tolmar
Speakers' Bureau - Amgen; Astellas Pharma; Bayer; Bristol-Myers Squibb; Ipsen; Janssen; Merck Serono; Novartis
Research Funding - Aptevo Therapeutics (Inst); Astellas Pharma; Astellas Pharma (Inst); AstraZeneca; AstraZeneca (Inst); Bionomics (Inst); Bristol-Myers Squibb (Inst); Exelixis (Inst); Gilead Sciences (Inst); GlaxoSmithKline (Inst); Hinova Pharmaceuticals (Inst); Ipsen (Inst); Janssen (Inst); Lilly (Inst); MedImmune (Inst); Merck Serono; Merck Serono (Inst); MSD (Inst); Novartis (Inst); Pfizer (Inst); Sanofi (Inst); Synthorx (Inst)
Travel, Accommodations, Expenses - Amgen; Astellas Pharma; Bayer; Hinova Pharmaceuticals; Janssen; Merck Serono; Pfizer; Sanofi; Tolmar
 
Michael Hofman
Consulting or Advisory Role - Janssen; MSD; Novartis (Inst)
Research Funding - Bayer (Inst); Debiopharm Group (Inst); Isotopia (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Debiopharm Group (Inst); Novartis